In a recent legal development, a New Jersey federal judge determined that five patents related to an inhaler manufactured by Teva Pharmaceuticals Industries Ltd. do not necessitate the presence of an active drug within the device. This decision aligns with Amneal Pharmaceuticals Inc.’s interpretation of the patent’s claim language in the ongoing infringement lawsuit filed by Teva against the generic pharmaceutical company. The ruling signifies a critical interpretation of the patent claims, potentially impacting the way inhaler patents are construed in the pharmaceutical industry.
For a detailed account of the ruling, visit the original article on Law360.